Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.

Literature DB >> 20165695

Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.

Erina Vlashi¹, Malcom Mattes, Chann Lagadec, Lorenza Della Donna, Tiffany M Phillips, Polin Nikolay, William H McBride, Frank Pajonk.

Abstract

Proteasome inhibitors are emerging as a new class of cancer therapeutics, and bortezomib has shown promise in the treatment of multiple myeloma and mantle cell lymphoma. However, bortezomib has failed to have an effect in preclinical models of glioma. NPI-0052 is a new generation of proteasome inhibitors with increased potency and strong inhibition of all three catalytic activities of the 26S proteasome. In this article, we test the antitumor efficacy of NPI-0052 against glioma, as a single agent and in combination with temozolomide and radiation using five different glioma lines. The intrinsic radiation sensitivities differed for all the lines and correlated with their PTEN expression status. In vitro, NPI-0052 showed a dose-dependent toxicity, and its combination with temozolomide resulted in radiosensitization of only the cell lines with a mutated p53. The effect of NPI-0052 as a single agent on glioma xenografts in vivo was only modest in controlling tumor growth, and it failed to radiosensitize the glioma xenografts to fractionated radiation. We conclude that NPI-0052 is not a suitable drug for the treatment of malignant gliomas despite its efficacy in other cancer types.

Entities: Chemical Disease Gene

Year: 2010 PMID： 20165695 PMCID： PMC2822455 DOI： 10.1593/tlo.09244

Source DB: PubMed Journal: Transl Oncol ISSN： 1936-5233 Impact factor: 4.243

35 in total

1. Survival of human glioma cells treated with various combination of temozolomide and X-rays.

Authors: J van Rijn; J J Heimans; J van den Berg; P van der Valk; B J Slotman
Journal: Int J Radiat Oncol Biol Phys Date: 2000-06-01 Impact factor: 7.038

2. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

Authors: Robert H Feling; Greg O Buchanan; Tracy J Mincer; Christopher A Kauffman; Paul R Jensen; William Fenical
Journal: Angew Chem Int Ed Engl Date: 2003-01-20 Impact factor: 15.336

3. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.

Authors: Stacey Ruiz; Yelena Krupnik; Michael Keating; Joya Chandra; Michael Palladino; David McConkey
Journal: Mol Cancer Ther Date: 2006-07 Impact factor: 6.261

4. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

Authors: Dong Yin; Hong Zhou; Takashi Kumagai; Gentao Liu; John M Ong; Keith L Black; H Phillip Koeffler
Journal: Oncogene Date: 2005-01-13 Impact factor: 9.867

5. Molecular pathways that modify tumor radiation response.

Authors: M Pervan; F Pajonk; J R Sun; H R Withers; W H McBride
Journal: Am J Clin Oncol Date: 2001-10 Impact factor: 2.339

6. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316

7. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.

Authors: Krista A van Nifterik; Jaap van den Berg; Lukas J A Stalpers; M Vincent M Lafleur; Sieger Leenstra; Ben J Slotman; Theo J M Hulsebos; Peter Sminia
Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-15 Impact factor: 7.038

8. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.

Authors: Christopher Lieu; Laura Chow; A Scott Pierson; S Gail Eckhardt; Cindy L O'Bryant; Mark Morrow; Zung Vu Tran; John J Wright; Lia Gore
Journal: Invest New Drugs Date: 2008-07-11 Impact factor: 3.850

Review 9. The ubiquitin-proteasome pathway in cancer.

Authors: V Spataro; C Norbury; A L Harris
Journal: Br J Cancer Date: 1998 Impact factor: 7.640

10. The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.

Authors: Frank Pajonk; Arndt van Ophoven; Christian Weissenberger; William H McBride
Journal: BMC Cancer Date: 2005-07-07 Impact factor: 4.430

14 in total

1. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.

Authors: Eduard H Panosyan; Yuntao Wang; Peng Xia; Wai-Nang Paul Lee; Youngju Pak; Dan R Laks; Henry J Lin; Theodore B Moore; Timothy F Cloughesy; Harley I Kornblum; Joseph L Lasky
Journal: Mol Cancer Res Date: 2014-02-06 Impact factor: 5.852

2. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.

Authors: Kaijun Di; G Kenneth Lloyd; Vivek Abraham; Ann MacLaren; Francis J Burrows; Annick Desjardins; Mohit Trikha; Daniela A Bota
Journal: Neuro Oncol Date: 2015-12-17 Impact factor: 12.300

3. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.

Authors: Young Dong Yoo; Dae-Hee Lee; Hyunjoo Cha-Molstad; Hyungsin Kim; Su Ran Mun; Changhoon Ji; Seong Hye Park; Ki Sa Sung; Seung Ah Choi; Joonsung Hwang; Deric M Park; Seung-Ki Kim; Kyung-Jae Park; Shin-Hyuk Kang; Sang Cheul Oh; Aaron Ciechanover; Yong J Lee; Bo Yeon Kim; Yong Tae Kwon
Journal: EMBO Rep Date: 2016-12-19 Impact factor: 8.807

Review 4. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Authors: B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino
Journal: Curr Cancer Drug Targets Date: 2011-03 Impact factor: 3.428

Review 5. The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors: Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal: Cell Mol Life Sci Date: 2021-07-31 Impact factor: 9.261